• Tue. Jun 6th, 2023

NRx Pharmaceuticals Builds on Its Intellectual Property Foundation for Neuropsychiatric Conditions, adds New U.S. Patent to Portfolio


Feb 25, 2023
RADNOR – NRx Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911.
This patent, issued… | February 23, 2023

Read More